Cullinan Therapeutics, Inc. (CGEM): R&D Expense
$187.40M
Year ended 2025-12-31
$171.47M
Trailing 12 months to 2026-06-30
+26.8%
3-year compound annual growth
+34.1%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $187.40M | +31.1% | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | $142.90M | -3.5% | 2026-03-10, From 2024-01-01 |
| 2023-12-31 | $148.16M | +61.1% | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | $91.95M | +59.2% | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | $57.75M | +33.6% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $43.21M | n/a | 2022-03-17, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | 2025-12-31 | $187.40M | +31.1% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $141.50M | +16.4% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $228.30M | +9.5% |
| Vor Biopharma Inc. (VOR) | 2025-12-31 | $321.53M | +244.6% |
| Sana Biotechnology, Inc. (SANA) | 2025-12-31 | $131.98M | -38.8% |
| Allogene Therapeutics, Inc. (ALLO) | 2025-12-31 | $150.15M | -21.9% |
| Vericel Corp (VCEL) | 2025-12-31 | $27.56M | +11.2% |
| Scholar Rock Holding Corp (SRRK) | 2025-12-31 | $208.44M | +12.9% |
| ImmunityBio, Inc. (IBRX) | 2024-12-31 | $190.14M | -18.2% |
Compare CGEM, GLUE, RGNX, VOR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗